ABL1 and acute lymphoblastic leukemia: <b>Background:</b> The advent of first- and second-generation BCR/ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib and dasatinib, has markedly improved the clinical outcomes of patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph<sup>+</sup>-ALL).